Navigation Links
Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research

GLEN ALLEN, Va., Oct. 18, 2011 /PRNewswire/ -- Rock Creek Pharmaceuticals, a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), has announced the expansion of international shipping destinations for purchases of its dietary supplement, Anatabloc™.  As the company indicated in an August 30 release that announced the product launch, Anatabloc™ contains the dietary ingredient anatabine citrate. Anatabine is an alkaloid that is found in a variety of plants in the Solinacea family, including the tobacco plant, as well as in eggplant, green peppers and green tomatoes.  Anatabine citrate, combined with Vitamins A and D3, is believed to assist the body in maintaining anti-inflammatory support. Excess inflammation is linked with a variety of auto-immune conditions that includes thyroid dysfunction, arthritis and Alzheimer's disease.  

(Photo: )


Rock Creek launched capacity for shipments to Canada, the United Kingdom, Australia and New Zealand, as well as 13 countries located in Europe, the Middle East and Asia, in late September.  Effective today Anatabloc can be shipped to an additional 29 countries:  Portugal, Monaco, Iceland, Hungary, Bulgaria, Poland, Austria, Finland, Norway, Sweden, Denmark, Brazil, Peru, Uruguay, Aruba, Bermuda, Barbados, Antigua, Cayman Islands, British Virgin Islands, Turks and Caicos, Bahamas, St. Lucia, St. Kitts and Nevis, San Marino, New Caledonia and Mexico.  

Consumers interested in purchasing the product will be able to either choose a "drop-down menu" on the product website ( that contains a list of all countries to which shipping is available, or to call the customer service center at 1-800-778-2031.  The company plans to continue exploring options for shipping to additional countries around the world, based on consumer demand for Anatabloc™. As new countries are added, they will be included in the shipping menu on the product website.

The company also announced that it is hosting the first of a series of Anatabloc conferences for physicians this evening in Richmond, Virginia.  Presentations on research using anatabine will be made by Michael Mullan, M.D. PhD, Director of the Roskamp Institute;  Paul Ladenson, MD, Director of Endocrinology & Metabolism at the Johns Hopkins School of Medicine; and Patrizio Caturegli, MD, MPH, Associate Professor of Pathology and Endocrinology at the John Hopkins School of Medicine.  Rock Creek intends to host two additional conferences for physicians and allied health care professionals in the Midwest and on the West Coast later this month.   Physicians and other licensed providers interested in viewing the presentations can contact for access.

Certain statements in this press release other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "continues," "likely," "may," "opportunity," "potential," "projects," "will," "expects," "plans," "intends" and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties, factors and contingencies include, without limitation, the challenges inherent in new product development initiatives through Star Tobacco and Rock Creek, the uncertainties inherent in the progress of scientific research, our ability to raise additional capital in the future that is necessary to maintain our business, potential disputes concerning our intellectual property, risks associated with litigation regarding such intellectual property, uncertainties associated with the development, testing and regulatory approvals of our low-TSNA tobacco,  related tobacco  products and pharmaceutical and nutraceutical products , market acceptance of our new smokeless tobacco products and nutraceutical  and pharmaceutical products, competition from companies with greater resources than us,  our dependence on key employees and on our prior strategic relationships with Brown & Williamson Tobacco Corporation in light of its combination with R.J. Reynolds Tobacco Company, Inc.

Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that the expectations will be attained or that any deviation will not be material. See additional discussion under "Risk Factors" in the Company's Annual Report on Form 10-K as filed with the SEC on March 16, 2011, and other factors detailed from time to time in the Company's other filings with the SEC, available at All information in this release is current as of this date, and the Company undertakes no obligation to update or advise upon any such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

About Star Scientific

Star Scientific is a technology-oriented company with a mission to reduce the harm associated with tobacco at every level. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins, principally   through the utilization of the innovative StarCured® tobacco curing technology.   Its subsidiary, Rock Creek Pharmaceuticals, Inc., is involved in the development of nutraceuticals as well as products to address neurological and mood disorders. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, D.C.  Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.  

See Star's website at:

Sara Troy Machir
Vice President, Communications & Investor Relations
(301) 654-8300

SOURCE Star Scientific
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rock Creek Pharmaceuticals Offers International Shipping Options for Anatabloc™
2. Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing
3. Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound
4. Swedish/Mill Creek Emergency Department, Ambulatory Care Center Opens Soon
5. Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer
6. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
7. First CyberKnife VSI System Installed at Creekside Cancer Care
8. Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
9. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
10. JHP Pharmaceuticals Enters Agreement to Produce Diagnostic Aid
11. Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals
Post Your Comments:
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... (PRWEB) , ... November 26, ... ... online platform for mental health and wellness consultation, has collaborated with Women’s ... holistically address their reader’s queries on topics on mental and emotional well-being ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Finnleo, a ... Christmas Eve on several models of traditional and far-infrared saunas. , For ... Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European Grade ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
Breaking Medicine News(10 mins):